Study of the Plasma and Buffy Coat in Patients with SARS-CoV-2 Infection-A Preliminary Report.
RNA
SARS-CoV-2
blood
buffy coat
immunohistochemical
morphology
plasma
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
25 Jun 2021
25 Jun 2021
Historique:
received:
09
05
2021
revised:
17
06
2021
accepted:
22
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
The pandemic caused by the SARS-CoV-2 infection affects many aspects of public health knowledge, science, and practice around the world. Several studies have shown that SARS-CoV-2 RNA in plasma seems to be associated with a worse prognosis of COVID-19. In the present study, we investigated plasma and buffy RNA in patients with COVID-19 to determine its prognostic value. A prospective study was carried out in patients hospitalized for COVID-19, in which RNA was analyzed in plasma and the buffy coat. Morphological and immunohistochemical studies were used to detect the presence of SARS-CoV-2 in the buffy coat. In COVID-19 patients, the obtained RNA concentration in plasma was 448.3 ± 31.30 ng/mL. Of all the patients with positive plasma tests for SARS-CoV-2, 46.15% died from COVID-19. In four cases, tests revealed that SARS-CoV-2 was present in the buffy coat. Abnormal morphology of monocytes, lymphocytes and neutrophils was found. An immunohistochemical study showed positivity in mononuclear cells and platelets. Our results suggest that SARS-CoV-2 is present in the plasma. This facilitates viral dissemination and migration to specific organs, where SARS-CoV-2 infects target cells by binding to their receptors. In our study, the presence of plasma SARS-CoV-2 RNA was correlated with worse prognoses.
Identifiants
pubmed: 34201967
pii: pathogens10070805
doi: 10.3390/pathogens10070805
pmc: PMC8308615
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Am J Clin Pathol. 2021 Apr 26;155(5):627-637
pubmed: 33502434
J Clin Virol. 2003 Dec;28(3):239-44
pubmed: 14522061
Virus Res. 2005 Jan;107(1):93-101
pubmed: 15567038
J Transl Med. 2020 Nov 2;18(1):412
pubmed: 33138836
Am J Clin Pathol. 2021 Feb 11;155(3):364-375
pubmed: 33269374
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Med Virol. 2020 Sep;92(9):1676-1680
pubmed: 32330305
Clin Infect Dis. 2020 Aug 17;:
pubmed: 32803231
BMC Infect Dis. 2021 Feb 17;21(1):184
pubmed: 33596855
EMBO Mol Med. 2020 Oct 7;12(10):e13038
pubmed: 32816392
Emerg Microbes Infect. 2020 Dec;9(1):469-473
pubmed: 32102625
J Clin Invest. 2021 Apr 1;131(7):
pubmed: 33561010
Clin Infect Dis. 2020 Aug 28;:
pubmed: 32856036
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
Viruses. 2020 Sep 18;12(9):
pubmed: 32962125
Clin Infect Dis. 2021 May 4;72(9):e291-e295
pubmed: 32965474
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
J Med Virol. 2020 Jun;92(6):548-551
pubmed: 32096567
Am J Hematol. 2020 Jul;95(7):870-872
pubmed: 32279346
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Emerg Microbes Infect. 2020 Dec;9(1):386-389
pubmed: 32065057
Cell. 2020 Apr 16;181(2):223-227
pubmed: 32220310
Cureus. 2021 Feb 18;13(2):e13416
pubmed: 33758711